⌕
AnaptysBio · ANAB · Nasdaq
Tenet 53 · Mixed
Compare
$45.61−0.26%At closeTenet 53 · Mixed
$45.61−0.12 (−0.26%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

AnaptysBio (ANAB) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

14 figures withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~38.8%/yr (FY21→FY25), net margin −5.6%. Worth your attention in FY25: Returns vs FCF (350%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲157.0%
234.6
FY21→FY25CAGR +38.8%/yr
Net income ($M)▲90.9%
−13.2
FY21→FY25CAGR —
Free cash flow ($M)—
19.6
FY21→FY25CAGR —
Diluted EPS▲91.0%
−0.46
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+4.8%

27.4mn → 28.8mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$87.0K

−75.7% YoY in FY25 · 0.0% of revenue.

Returns vs FCF
350%

$68.6M returned vs $19.6M of FCF in FY25. The gap comes off the balance sheet (see net cash).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)234.6Revenue0.0COGS−136.0R&D−50.7SG&A47.9Op income−61.1Tax & other−13.2Net income

-6¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -5.6% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—234,603.091,280.017,157.010,287.063,175.0▲157.0%+38.8%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
——A—A—A10,287.063,175.0——
Research & development
—135,970.0163,840.0139,622.088,798.098,496.0▼17.0%+8.4%
Selling, general & admin
—50,737.042,389.041,946.036,643.021,493.0▲19.7%+24.0%
Total operating expenses
—186,707.0206,229.0181,568.0125,441.0119,989.0▼9.5%+11.7%
Operating incomefeeds ROC rank
—47,896.0−114,949.0−164,411.0−115,154.0−56,814.0——
Other income, net
—−60,964.0−30,279.0788.0−13,546.0−982.0——
Pretax income
—−13,068.0−145,228.0−163,623.0−128,700.0−57,796.0▲91.0%—
Income tax
—164.03.0−4.024.00.0▲5366.7%+89.8% (22→25)
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
—−13,232.0−145,231.0−163,619.0−128,724.0−57,796.0▲90.9%—
Per share
Diluted EPSbuyback-sensitive
—−0.46−5.12−6.08−4.57−2.11▲91.0%—
Diluted shares (mn)
35.0728.7628.3826.9228.1627.43▲1.3%+1.2%
Margins
Gross margin
——A—A—A100.0%100.0%——
Operating margin
—20.4%−125.9%−958.3%−1119.4%−89.9%▲146.3pp+110.3pp
Net margin32nd pct in Healthcare
—−5.6%−159.1%−953.7%−1251.3%−91.5%▲153.5pp+85.8pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY15 – FY20 · 6 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was AnaptysBio's revenue last fiscal year?

AnaptysBio reported revenue of $234.6M in fiscal 2025, up 157.0% from fiscal 2024.

What was AnaptysBio's net income?

AnaptysBio reported net income of −$13.2M in fiscal 2025, a net margin of −5.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.